Office Headquarters: (610) 544-3500

perirx log in button

PeriRx Logo


Get News and Updates



CLIA: 39D2085645

PeriRx on Facebook PeriRx on YouTube PeriRx on Google+ Stephen M. Swanick LinkedIn


New York State has a separate and unique regulatory approval process for laboratory diagnostic testing. PeriRx is currently in the application process with our SaliMark™ OSCC test and is vigorously committed to pursuing this application approval. 

PeriRX Webinar

Course Title:

Salivary Diagnostics and The Efficacy of SaliMark™ OSCC for the Early Detection of Oral Squamous Cell Carcinoma


Register for FREE CE Course


To successfully complete the webinar, you must use the following browsers: Firefox, Chrome and Safari. Our Webinar cannot be supported in older versions of Internet Explorer (versions earlier than 9). For best results, please use Chrome or Firefox.

Course Description:

This slide program reviews the incidence as well as the morbidity and mortality of oral squamous cell carcinoma. The scientific background of salivary molecular diagnostics is presented along with the clinical trials that lead to the development of the SaliMark™ OSCC. The clinical use of salivary testing in oral cancer screening protocols is reviewed.

Two publications are also provided for review. The article in Dentistry Today discusses the use of salivary biomarkers for other systemic diseases in addition to oral cancer. The second article is the Compendium, which provides in depth knowledge of the scientific trial data for the oral squamous cell salivary markers.

After answering true/false questions for each segment the user can print a CE certificate. A total of 3.5 CEs are offered.

After completing this course you will have an in depth knowledge of the following:

  • Oral Cancer Statistics and Demographics
  • Who is at Risk for Oral Cancer?
  • Disease Stages and Prognosis
  • The Value of Salivary Diagnostics for Early Detection
  • The Science Behind SaliMark™ OSCC
  • Product Use and Insurance Guidelines